Global Decoquinate Market - Region-wise Outlook and Segments

Decoquinate Market: Overview

Get a Free Sample Report:
http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=11798

Decoquinate (ethyl 6-decoxy-7-ethoxy-4-oxo-1H-quinoline-3-carboxylate) is an antiprotozoal agent that acts against coccidia parasites (coccidiostat). This drug is majorly used in veterinary medicines. Decoquinate acts on the sporozoite stage of the coccidian parasite life cycle. The sporozoite apparently penetrates the host intestinal call and prevents the further development. Decoquinate has low toxicity levels and is administered by the oral route in a range of mammalian and avian species.

Various studies conducted on decoquinate suggested that the drug is well tolerated by a range of possible targeted species including cattle and lambs while studies conducted on rats and dogs, the minor changes in food consumption, feed conversion, subdued behavior and changes in body weight and organ weight were observed in some of the animals.

Decoquinate Market: Segmentation

The market for decoquinate could be segmented depending on the type of formulations which are as follows:

Powder
Tablet
Nanoparticles

Decoquinate in the powder form dominates the decoquinate market owing to its ease of usage. Decoquinate in the powder form is added to animal feed which helps the drug to be absorbed quickly. Decoquinate when provided in powder form reaches the effective concentration within an hour. However nanoparticles formulation is the fastest growing segment in the Decoquinate market due to added advantages over the powder form. According to a study conducted on mice at Walter Reed Army Institute of Research, Silver Spring, MD, US, oral administration of nanoparticle decoquinate to mice effectively repressed the liver-stage parasite growth and helped in providing the complete casual prophylactic protection. The efficiency of nanoparticle decoquinate was observed as 15 times superior than that observed for microparticle decoquinate used for powder and tablet formulations.

Moreover, the dosage provided to the mice that is 1.25mg/kg was also very less in comparison to dosage provided through powder and tablets which is 20 mg/kg. All the above mentioned factors are encouraging the market players and researchers to develop more effective nanoparticle decoquinate for use in veterinary medicines.

Decoquinate Market: Region-wise Outlook

Geographically, the decoquinate market has been classified into four segments: North America, Europe, Asia Pacific and Rest of the World. North America and Europe currently dominate the decoquinate market majorly due to strong economic conditions and huge population of cattle. The major market of Europe is driven by Switzerland, which is known for cows and cattle. In 2010, there were 1,591,233 cattle in Switzerland. Additionally, the government of U.S. and Europe has also setup some regulatory firms which are also helping the market to grow. As in Canada, Canadian food inspection agency (CFIA) provides grants and funds for developing new and novel veterinary biologics and animal health products such as antibody products, vaccines, diagnostic kits which are used for the prevention, treatment and diagnosis of infectious diseases in animals. These grants help researchers in developing new and novel decoquinate formulations, hence driving the market.

Asia Pacific market is also growing rapidly for decoquinate market due to increasing awareness among the usage of decoquinate among cattle and poultry animals.

Decoquinate Market: Key Players

Many major pharmaceutical companies are involved in manufacturing decoquinate formulations. Major market player among them include Alpharma, subsidiary of Pfizer’s Inc. The company offers deccox, 3 nitro, albac, chlormax, lincomycin, rumicox and many other decoquinate formulations in its portfolio. Other major brands names include Laboratories Biové’s acti decocci and lacto decocci, Pharmacia & Upjohn Company’s lincomix, Pennfield’s Animal Health’s pennchlor, Sogeval Laboratories’ rumicox and Qualian’s ucamix v decoquinate.

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who us e proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

90 State Street, Suite 700 Albany, NY 12207

This release was published on openPR.